Philip Bonomi to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Philip Bonomi has written about Clinical Trials, Phase III as Topic.
Connection Strength
1.024
-
Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010 Mar 01; 116(5):1155-64.
Score: 0.371
-
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9.
Score: 0.143
-
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45.
Score: 0.114
-
Lung cancer: new developments point the way to reduced mortality. Oncology (Williston Park). 2011 Jan; 25(1):82, 84.
Score: 0.098
-
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74.
Score: 0.088
-
Treatment of locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol. 2009 Jul; 7(7):455-64, 479-80.
Score: 0.088
-
Chemoradiation in locally advanced non-small cell lung cancer. Cancer Treat Res. 2001; 105:171-88.
Score: 0.049
-
Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):13S-16S.
Score: 0.040
-
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006 May; 7(6):417-9.
Score: 0.018
-
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004 May; 40(8):1193-8.
Score: 0.015